<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K/A
AMENDMENT NO. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 14, 1997
------------------
BIOJECT MEDICAL TECHNOLOGIES INC.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Oregon
----------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-15360 93-1099680
------------------------ --------------------------------
(Commission File Number) (IRS Employer Identification No.)
7620 SW Bridgeport Road
Portland, Oregon 97224
- --------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (503) 639-7221
--------------
N/A
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE> 2
Item 5. Other events.
In December 1996, the Company completed a private placement of common stock
and warrants. Net proceeds received totalled $2.163 million in exchange for
approximately 3.4 million shares of the Company's common stock and five year
warrants to purchase approximately 3.4 million shares of common stock at $1.00
per share. Preferred Technology, Inc. acted as agent in connection with a
portion of the Placement and, in connection therewith, received a placement fee
of $107,640 and a warrant to acquire 156,000 shares of common stock at an
exercise price of $0.828125 per share. Veber Partners acted as an agent in
connection with a portion of the Placement and, in connection therewith,
received a fee of $34,860. As a result of this transaction, the Company was
again in compliance with NASDAQ net tangible assets listing requirements.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOJECT MEDICAL TECHNOLOGIES INC.
Date: January 22, 1998 By /s/ Peggy J. Miller
----------------------------------
Peggy J. Miller
Vice President, Chief Financial
Officer, Secretary/Treasurer
